Emergent Biosolutions Long Term Debt

The latest long-term debt for EBS is $570M as of March 2026. That compares with $670M in the prior-year period — down 13.8% year over year. Investors often review this figure alongside Emergent Biosolutions's historical trend and sector peers before judging valuation or financial health.

Over the past year, EBS's long-term debt moved from $670M to $570M — a 13.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Emergent Biosolutions's operating scale or balance-sheet position.

A long-term debt figure of $570M for EBS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting EBS's long-term debt ($570M), review year-over-year change from $670M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Emergent Biosolutions's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.